Search bioRxiv⌕ Search

Biology subjects

Podolskiy, D.

Publications and source records attributed to Podolskiy, D..

2 recordsLinked to original sources

Ratiometric Quantification of Dissolved Molecular Oxygen in Microplates for Biochemical Assays Using Palladium Porphyrin Photoluminescence

Many biochemical processes are dependent on the presence or absence of molecular oxygen (O2). Palladium-tetrapyrrol derivatives can be used to measure O2-concentrations and O2-turnover during biochemical reactions and microbial growth in standard microtiter plates (MTPs). Palladium(II)-5,10,15,20-(tetrapentafluorophenyl)-porphyrin (1; CAS 72076-09-6) and Palladium(II)-5,10,15,20-(tetraphenyl)tetrabenzoporphyrin (2; CAS 119654-64-7) are introduced with this study. Spectral analyses of both compounds revealed that fluorescence quenching by O2 is not evenly distributed throughout all wavelengths and can therefore be used ratiometrically. Experimentally determined fluorescence lifetimes are around 500 {micro}s and 300 {micro}s for 1 and 2, respectively. A simple protocol is disclosed, how to immobilize the indicators on the bottom of MTP wells to give clear transparent dye doped polymer layers. We propose a straightforward procedure of how fluorescence data can be processed and calibrated in terms of O2 concentrations. Diverse applications are demonstrated and discussed, which include oxygen consumption and production by microorganisms as well as by enzymatically catalysed biochemical reactions. Various aspects are critically considered, as there are e.g. the dependence of O2 solubility on temperature and salinity, the diffusion of O2 across diverse phase boundaries, the unwanted O2 ingress into the reaction volume, the oxygen binding capacity of the MTP plastic material and the pH-dependence of the sensor layer. The findings and methods presented here open up a broad variety of high throughput assays involving changes of dissolved O2 as measurands for biochemical and biological activity. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=98 SRC="FIGDIR/small/718663v1_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@4daa4dorg.highwire.dtl.DTLVardef@e7ab8aorg.highwire.dtl.DTLVardef@1af1149org.highwire.dtl.DTLVardef@97fea5_HPS_FORMAT_FIGEXP M_FIG C_FIG

biophysics↗

Scalable Generation of Universal hiPSC-Derived Vascular Progenitor Cells for Safe and Sustained Revascularization in Chronic Limb-Threatening Ischemia

BackgroundChronic limb-threatening ischemia (CLTI) is the most severe form of peripheral artery disease and can result in debilitating tissue damage, limb loss, and mortality if left untreated. Despite surgical bypass and endovascular interventions, there is high unmet need to develop novel therapies that can restore durable blood flow and rescue limb function in patients whose disease is not amenable to surgical bypass and endovascular procedures. Human induced pluripotent stem cell (hiPSC)-derived vascular progenitor cells (VPC) hold promise for addressing this unmet need, yet their clinical adoption will require a scalable and consistently high-quality cell product that can be used safely in a large number of CLTI patients. MethodsHere, we report a robust, scalable GMP-adaptable platform for generating universally immuno-compatible VPC from human leukocyte antigen (HLA) class I/II-edited hiPSCs with extensive characterization of phenotypic and functional attributes critical to address key translational gaps in developing cell-based therapies for CLTI. We have interrogated their therapeutic efficacy in multiple murine CLTI models using a combination of clinically relevant endpoints, histology, and tissue-based RNAseq analysis. ResultsWe found that VPC-treated mice exhibited significantly improved perfusion ratios and preserved limb function, reduced inflammation, and increased physiological neovascularization without pathological malformations. ConclusionsGenetic modification conferring hypoimmune status coupled with a robust differentiation process enables large scale production of an "off-the shelf" high-quality VPC product with the potential to address unmet need in CLTI patients regardless of HLA status.

cell biology↗